Learn about gene and cell therapies.
Improved patient stratification will allow for a better understanding of disease course/kinetics and with this, better trials
A greater recognition of prodromal Parkinson's disease may aid diagnosis and shift many disease modifying trials to an earlier disease stage including cell and gene based therapies
The new trials of biological dopaminergic therapies including stem cell derived dopaminergic neurons are coming to a clinic soon but will only be useful in those who already do well with other DA/DBS therapies so competitiveness will be critical if they are to survive.
Presenter: Roger Barker, MBBS, MRCP, PhD
Professor of Clinical Neuroscience and Honorary Consultant, Neurology, University of Cambridge and Addenbrooke’s Hospital in the United Kingdom
